Abstract
The methylation status of the O6-methylguanine-methyltransferase promoter (MGMTP) was evaluated in 68 low-grade gliomas treated by neoadjuvant temozolomide. Methylated MGMTP was detected in 63 of 68 (92.6 %) patients and was a favorable predictor of progression-free survival as compared with unmethylated MGMTP tumors (p < 0.0001). Assessment of MGMTP status could help identifying low-grade gliomas patients more likely to respond to chemotherapy or to benefit from MGMT depletion strategies.
Publication types
-
Clinical Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Agents, Alkylating / pharmacology
-
Antineoplastic Agents, Alkylating / therapeutic use
-
Biomarkers, Tumor / genetics*
-
Brain Neoplasms / diagnosis
-
Brain Neoplasms / drug therapy*
-
Brain Neoplasms / genetics
-
DNA Methylation / drug effects*
-
DNA Modification Methylases
-
DNA Mutational Analysis
-
DNA Repair Enzymes
-
Dacarbazine / analogs & derivatives*
-
Dacarbazine / pharmacology
-
Dacarbazine / therapeutic use
-
Disease Progression
-
Female
-
Genetic Markers / drug effects
-
Genetic Markers / genetics
-
Glioma / diagnosis
-
Glioma / drug therapy*
-
Glioma / genetics
-
Humans
-
Male
-
Middle Aged
-
Neoadjuvant Therapy
-
Predictive Value of Tests
-
Prognosis
-
Promoter Regions, Genetic / drug effects*
-
Promoter Regions, Genetic / genetics
-
Survival Rate
-
Temozolomide
-
Tumor Suppressor Protein p14ARF / genetics*
-
Tumor Suppressor Proteins
Substances
-
Antineoplastic Agents, Alkylating
-
Biomarkers, Tumor
-
Genetic Markers
-
Tumor Suppressor Protein p14ARF
-
Tumor Suppressor Proteins
-
Dacarbazine
-
DNA Modification Methylases
-
MGMT protein, human
-
DNA Repair Enzymes
-
Temozolomide